Back to Menu
Craniopharyngioma is a WHO grade I benign epithelial tumor arising from residual epithelial cells of the embryonic craniopharyngeal duct and is most commonly located in the sellar region. Although histologically benign, it is deeply seated and adjacent to the optic apparatus, pituitary gland, and hypothalamus. Clinical manifestations are complex, treatment is challenging, recurrence is common, and neuroendocrine sequelae can be substantial.
1. Adamantinomatous type
The most common subtype, accounting for approximately 90% of cases, and more frequent in children. It is often cystic–solid, with “machine oil–like” cyst fluid, and shows palisading epithelial arrangements.
2. Papillary type
Seen almost exclusively in adults. Tumors are typically predominantly solid, lack characteristic palisading, and have a relatively higher likelihood of complete resection.
3. Imaging and surgical classification
Based on growth location, tumors may be intrasellar, suprasellar, or intraventricular. Surgical risk is assessed according to the degree of adhesion to the hypothalamus.
1. Embryonic origin hypothesis
Arises from embryonic remnants of squamous epithelium within the craniopharyngeal duct that undergo abnormal proliferation and ultimately form a tumor.
2. Genetic alterations
CTNNB1 mutations are common in the adamantinomatous type, whereas BRAF V600E mutations are common in the papillary type, driving tumor growth.
3. Congenital factors
Directly related to developmental remnants and may occur at any age, without clear familial aggregation.
4. Other factors under investigation
Rarely, prior cranial radiotherapy may be implicated; there is no evidence that lifestyle or environmental factors directly cause the disease.
1. Recognize abnormal symptoms and seek early care
Be vigilant for growth retardation or visual decline in children, and headache or endocrine disturbances in adults, and seek neurosurgical evaluation promptly.
2. Lifelong surveillance and monitoring
Regular cranial MRI is required to monitor recurrence, together with endocrine testing and adjustment of replacement therapy and formal visual acuity and visual field assessments.
3. Strict adherence to endocrine replacement therapy
Follow replacement regimens carefully and do not adjust doses or discontinue medications without medical advice. Carry a medical information card to inform providers during emergencies.
4. Healthy lifestyle and complication management
Actively manage body weight and prevent obesity, and monitor risks such as osteoporosis, dyslipidemia, and cardiovascular disease.
5. Psychological support and social reintegration
Seek family and psychological support and engage in rehabilitation. Patients are encouraged to return to normal learning, work, and social activities when feasible.
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that although craniopharyngioma is benign, it can cause permanent visual and endocrine impairment. After diagnosis, active and standardized treatment is required, with goals of tumor control and functional reconstruction. A lifelong management plan developed by an MDT is essential to achieve optimal outcomes.
Craniopharyngioma is a WHO grade I benign epithelial tumor arising from residual epithelial cells of the embryonic craniopharyngeal duct and is most commonly located in the sellar region. Although histologically benign, it is deeply seated and adjacent to the optic apparatus, pituitary gland, and hypothalamus. Clinical manifestations are complex, treatment is challenging, recurrence is common, and neuroendocrine sequelae can be substantial.
1. Adamantinomatous type
The most common subtype, accounting for approximately 90% of cases, and more frequent in children. It is often cystic–solid, with “machine oil–like” cyst fluid, and shows palisading epithelial arrangements.
2. Papillary type
Seen almost exclusively in adults. Tumors are typically predominantly solid, lack characteristic palisading, and have a relatively higher likelihood of complete resection.
3. Imaging and surgical classification
Based on growth location, tumors may be intrasellar, suprasellar, or intraventricular. Surgical risk is assessed according to the degree of adhesion to the hypothalamus.
1. Embryonic origin hypothesis
Arises from embryonic remnants of squamous epithelium within the craniopharyngeal duct that undergo abnormal proliferation and ultimately form a tumor.
2. Genetic alterations
CTNNB1 mutations are common in the adamantinomatous type, whereas BRAF V600E mutations are common in the papillary type, driving tumor growth.
3. Congenital factors
Directly related to developmental remnants and may occur at any age, without clear familial aggregation.
4. Other factors under investigation
Rarely, prior cranial radiotherapy may be implicated; there is no evidence that lifestyle or environmental factors directly cause the disease.
1. Recognize abnormal symptoms and seek early care
Be vigilant for growth retardation or visual decline in children, and headache or endocrine disturbances in adults, and seek neurosurgical evaluation promptly.
2. Lifelong surveillance and monitoring
Regular cranial MRI is required to monitor recurrence, together with endocrine testing and adjustment of replacement therapy and formal visual acuity and visual field assessments.
3. Strict adherence to endocrine replacement therapy
Follow replacement regimens carefully and do not adjust doses or discontinue medications without medical advice. Carry a medical information card to inform providers during emergencies.
4. Healthy lifestyle and complication management
Actively manage body weight and prevent obesity, and monitor risks such as osteoporosis, dyslipidemia, and cardiovascular disease.
5. Psychological support and social reintegration
Seek family and psychological support and engage in rehabilitation. Patients are encouraged to return to normal learning, work, and social activities when feasible.
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that although craniopharyngioma is benign, it can cause permanent visual and endocrine impairment. After diagnosis, active and standardized treatment is required, with goals of tumor control and functional reconstruction. A lifelong management plan developed by an MDT is essential to achieve optimal outcomes.